Business
PRTC Provides Recap Ahead of Catalyst-Rich 2023
PRTC Provides Recap Ahead of Catalyst-Rich 2023.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n 22 December 2022\n \n \n \n \n PureTech Health plc\n \n \n \n \n \n \n \n \n \n PureTech Provides End of Year Report on Key Progress\n \n \n \n \n \n \n \n \n \n Rapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone). Robust dose escalation and safety data also announced from completed monotherapy portion of Phase 1 program for LYT-200 (anti-galectin-9 mAb)\n \n \n \n \n \n \n \n \n \n Catalyst-rich 2023 anticipated, with results from late-stage trial of LYT-100 in idiopathic pulmonary fibrosis and Phase 1b trial of LYT-200 in leukemia. Initiation of clinical trials planned with LYT-300 and LYT-310 (oral cannabidiol) targeting neurological conditions as well as the combination portion of the Phase 1 trial of LYT-200 in solid tumors\n \n \n \n \n \n \n \n \n \n Continued momentum across Founded Entities, including Karuna's positive Phase 3 results for KarXT in schizophrenia, commercial progress for Gelesis' Plenity® and Akili's EndeavorRx® and Vor's promising initial data in acute myeloid leukemia\n \n \n \n \n \n \n \n Board composition and committee changes also noted\n \n \n \n \n \n \n \n \n \n PureTech Health plc\n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today reported on the key progress made across its Wholly Owned Programs[1] and Founded Entities[2] in 2022.\n \n \n \n \n Daphne Zohar, Founder and Chief Executive Officer of PureTech, commented: \"2022 has been a particularly successful and productive year in both crystallizing value and shaping the future of PureTech. Our primary focus is to progress our Wholly Owned Pipeline to commercialization and deliver new classes of medicines for patients with serious, debilitating conditions. We are advancing toward this goal by deepening our commitment to programs with compelling clinical data that are moving into late-stage studies and that we believe have the potential for broad impact.\n \n \"Over the next 12 months, we anticipat...